Key Efficacy Data from PERSEUS in Newly Diagnosed Multiple Myeloma

Opinion
Video

Myeloma specialists provide comprehensive insights on key data from the PERSEUS trial evaluating MRD status in patients receiving DARA-VRd and VRd.

Video content above is prompted by the following questions:

  • What are your initial impressions of the efficacy data from PERSEUS?
  • What are the potential clinical implications of this data in your practice for TE NDMM patients?
  • How might this data impact the current treatment landscape?
Recent Videos
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
2 experts in this video
2 experts in this video
Related Content